US FDA warns Pierre Fabre on Aloxi manufacturing deviations
This article was originally published in Scrip
Executive Summary
The US FDA has cited Pierre Fabre Medicament for significant violations in the company's manufacture of Helsinn/Eisai's anti-emetic Aloxi (palonosetron) at a new facility in Idron, France.